+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Chronic Kidney Disease Market by Type, Indication, End-User - Global Forecast 2025-2030- Product Image
Chronic Kidney Disease Market by Type, Indication, End-User - Global Forecast 2025-2030- Product Image
Sale

Chronic Kidney Disease Market by Type, Indication, End-User - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 189 Pages
  • October 2024
  • Region: Global
  • 360iResearch™
  • ID: 5977705
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Chronic Kidney Disease Market grew from USD 128.45 billion in 2023 to USD 136.56 billion in 2024. It is expected to continue growing at a CAGR of 6.50%, reaching USD 199.64 billion by 2030.

Chronic Kidney Disease (CKD) encompasses a range of conditions where the kidneys progressively lose function, adversely impacting the body's ability to filter waste from the blood. This disease eventually leads to kidney failure and necessitates dialysis or transplantation. The necessity for CKD management is driven by its prevalence and the associated health burden, making its diagnostics and treatments crucial in healthcare. CKD applications focus on therapeutics, dialysis solutions, and kidney transplantation, with end-use spanning hospitals, dialysis centers, and research institutions. The market for CKD treatment is influenced by factors like the rising incidence of diabetes and hypertension, increased awareness, and better healthcare infrastructure. Additionally, technological advancements in diagnostic practices and therapeutic developments propel market growth. Opportunities lie in developing personalized medicine approaches, advanced biopharmaceuticals, and telemedicine solutions to make treatments more accessible. However, challenges persist, such as high treatment costs, lack of awareness in underdeveloped regions, and supply chain inconsistencies, which can impede market expansion. Regulations and reimbursement policies also add complexity to market dynamics. To capitalize on potential growth opportunities, companies should focus on research in biomarker identification for early detection, development of affordable treatment alternatives, and integrating AI in treatment methodology to enhance efficacy. Emphasizing patient education initiatives can expand reach and market penetration. The CKD market operates in a competitive landscape with major pharmaceutical and biotech firms contributing significantly to innovation and growth. Research on regenerative medicine and kidney tissue engineering holds promise for groundbreaking improvements. For business growth, leveraging strategic partnerships, fostering product differentiation, and investing in market segmentation strategies will be key. Insight into regional disparities in CKD prevalence and healthcare capability presents a frontier for targeted interventions and tapping into untapped markets.

Understanding Market Dynamics in the Chronic Kidney Disease Market

The Chronic Kidney Disease Market is rapidly evolving, shaped by dynamic supply and demand trends. These insights provide companies with actionable intelligence to drive investments, develop strategies, and seize emerging opportunities. A comprehensive understanding of market dynamics also helps organizations mitigate political, geographical, technical, social, and economic risks while offering a clearer view of consumer behavior and its effects on manufacturing costs and purchasing decisions.
  • Market Drivers
    • Increasing global prevalence of chronic kidney disease with the aging population
    • Supportive government and regulatory policies aimed at improving healthcare infrastructure
    • Growing public and medical community awareness regarding early screening and diagnosis of kidney ailments
  • Market Restraints
    • High cost and gap in product standardization across regions
  • Market Opportunities
    • Advancements in treatment and diagnostic technologies and product innovation
    • Expansion of telemedicine and remote monitoring technologies
  • Market Challenges
    • Limited commercialization of advanced kidney disease treatments

Exploring Porter’s Five Forces for the Chronic Kidney Disease Market

Porter’s Five Forces framework further strengthens the insights of the Chronic Kidney Disease Market, delivering a clear and effective methodology for understanding the competitive landscape. This tool enables companies to evaluate their current competitive standing and explore strategic repositioning by assessing businesses’ power dynamics and market positioning. It is also instrumental in determining the profitability of new ventures, helping companies leverage their strengths, address weaknesses, and avoid potential pitfalls.

Applying PESTLE Analysis to the Chronic Kidney Disease Market

External macro-environmental factors deeply influence the performance of the Chronic Kidney Disease Market, and the PESTLE analysis provides a comprehensive framework for understanding these influences. By examining Political, Economic, Social, Technological, Legal, and Environmental elements, this analysis offers organizations critical insights into potential opportunities and risks. It also helps businesses anticipate changes in regulations, consumer behavior, and economic trends, enabling them to make informed, forward-looking decisions.

Analyzing Market Share in the Chronic Kidney Disease Market

The Chronic Kidney Disease Market share analysis evaluates vendor performance. This analysis provides a clear view of each vendor’s standing in the competitive landscape by comparing key metrics such as revenue, customer base, and other critical factors. Additionally, it highlights market concentration, fragmentation, and trends in consolidation, empowering vendors to make strategic decisions that enhance their market position.

Evaluating Vendor Success with the FPNV Positioning Matrix in the Chronic Kidney Disease Market

The Chronic Kidney Disease Market FPNV Positioning Matrix is crucial in evaluating vendors based on business strategy and product satisfaction levels. By segmenting vendors into four quadrants - Forefront (F), Pathfinder (P), Niche (N), and Vital (V) - this matrix helps users make well-informed decisions that best align with their unique needs and objectives in the market.

Strategic Recommendations for Success in the Chronic Kidney Disease Market

The Chronic Kidney Disease Market strategic analysis is essential for organizations aiming to strengthen their position in the global market. A comprehensive review of resources, capabilities, and performance helps businesses identify opportunities for improvement and growth. This approach empowers companies to navigate challenges in the increasingly competitive landscape, ensuring they capitalize on new opportunities and align with long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Kidney Disease Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allmed Medical Products Co., Ltd., AngioDynamics, Inc., Apotex Inc., Asahi Kasei Corporation, AstraZeneca PLC, B. Braun SE, Baxter International, Inc., Becton, Dickinson and Company, Centessa Pharmaceuticals Limited, DaVita Inc., Dialife SA, Dr. Reddys Laboratories Ltd., Evoqua Water Technologies LLC, Fresenius Medical Care AG, Galapagos NV, Hemoclean Co. Ltd., JMS Co., Ltd., Johnson & Johnson Services, Inc., Medtronic PLC, Merck & Co., Inc., Nikkiso Co., Ltd., Nipro Corporation, Novartis AG, NxStage Medical Inc., Otsuka Pharmaceutical Co., Ltd., Reata Pharmaceuticals Inc., Rockwell Medical Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Medical Co., Ltd., Trivitron Healthcare, and XORTX Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Chronic Kidney Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:
  • Type
    • Diagnosis
      • Blood Tests
      • Imaging Tests
      • Kidney Biopsy
      • Urine Tests
    • Treatment
      • Dialysis
      • Kidney Transplant
      • Medication
        • ACE Inhibitors
        • Angiotensin Receptor Blockers
        • Beta Blockers
        • Diuretics
        • Erythropoietin Stimulants
        • Finerenone
        • Glucagon-like Peptide-1 Receptor Agonists
        • Insulin
        • Metformin
        • Potassium Binders
        • Sodium-glucose Cotransporter-2 Inhibitors
        • Statins
  • Indication
    • Chronic Interstitial Nephritis
    • Diabetic Nephropathy
    • Glomerulonephritis
    • Hypertensive Nephropathy
    • Obstructive Nephropathy
    • Polycystic Kidney Disease
  • End-User
    • Ambulatory Surgery Centers
    • Diagnostic Centers & Laboratories
    • Hospitals & Clinics
    • Speciality Treatment Centers
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report provides a detailed overview of the market, exploring several key areas:

  1. Market Penetration: A thorough examination of the current market landscape, featuring comprehensive data from leading industry players and analyzing their reach and influence across the market.
  2. Market Development: The report identifies significant growth opportunities in emerging markets and assesses expansion potential within established segments, providing a roadmap for future development.
  3. Market Diversification: In-depth coverage of recent product launches, untapped geographic regions, significant industry developments, and strategic investments reshaping the market landscape.
  4. Competitive Assessment & Intelligence: A detailed analysis of the competitive landscape, covering market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, technological advancements, and innovations in manufacturing by key market players.
  5. Product Development & Innovation: Insight into groundbreaking technologies, R&D efforts, and product innovations that will drive the market in future.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current size of the market, and how is it expected to grow?
  2. Which products, segments, and regions present the most attractive investment opportunities?
  3. What are the prevailing technology trends and regulatory factors influencing the market?
  4. How do top vendors rank regarding market share and competitive positioning?
  5. What revenue sources and strategic opportunities guide vendors' market entry or exit decisions?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing global prevalence of chronic kidney disease with the aging population
5.1.1.2. Supportive government and regulatory policies aimed at improving healthcare infrastructure
5.1.1.3. Growing public and medical community awareness regarding early screening and diagnosis of kidney ailments
5.1.2. Restraints
5.1.2.1. High cost and gap in product standardization across regions
5.1.3. Opportunities
5.1.3.1. Advancements in treatment and diagnostic technologies and product innovation
5.1.3.2. Expansion of telemedicine and remote monitoring technologies
5.1.4. Challenges
5.1.4.1. Limited commercialization of advanced kidney disease treatments
5.2. Market Segmentation Analysis
5.2.1. Type: Growing need for chronic kidney disease diagnosis solutions to determine the function of the kidneys
5.2.2. End-User: Growing accessibility of chronic kidney disease treatments through hospitals & clinics as they offer a broad range of services
5.3. Porter’s Five Forces Analysis
5.3.1. Threat of New Entrants
5.3.2. Threat of Substitutes
5.3.3. Bargaining Power of Customers
5.3.4. Bargaining Power of Suppliers
5.3.5. Industry Rivalry
5.4. PESTLE Analysis
5.4.1. Political
5.4.2. Economic
5.4.3. Social
5.4.4. Technological
5.4.5. Legal
5.4.6. Environmental
6. Chronic Kidney Disease Market, by Type
6.1. Introduction
6.2. Diagnosis
6.2.1. Blood Tests
6.2.2. Imaging Tests
6.2.3. Kidney Biopsy
6.2.4. Urine Tests
6.3. Treatment
6.3.1. Dialysis
6.3.2. Kidney Transplant
6.3.3. Medication
6.3.3.1. ACE Inhibitors
6.3.3.2. Angiotensin Receptor Blockers
6.3.3.3. Beta Blockers
6.3.3.4. Diuretics
6.3.3.5. Erythropoietin Stimulants
6.3.3.6. Finerenone
6.3.3.7. Glucagon-like Peptide-1 Receptor Agonists
6.3.3.8. Insulin
6.3.3.9. Metformin
6.3.3.10. Potassium Binders
6.3.3.11. Sodium-glucose Cotransporter-2 Inhibitors
6.3.3.12. Statins
7. Chronic Kidney Disease Market, by Indication
7.1. Introduction
7.2. Chronic Interstitial Nephritis
7.3. Diabetic Nephropathy
7.4. Glomerulonephritis
7.5. Hypertensive Nephropathy
7.6. Obstructive Nephropathy
7.7. Polycystic Kidney Disease
8. Chronic Kidney Disease Market, by End-User
8.1. Introduction
8.2. Ambulatory Surgery Centers
8.3. Diagnostic Centers & Laboratories
8.4. Hospitals & Clinics
8.5. Speciality Treatment Centers
9. Americas Chronic Kidney Disease Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Chronic Kidney Disease Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Chronic Kidney Disease Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. Market Share Analysis, 2023
12.2. FPNV Positioning Matrix, 2023
12.3. Competitive Scenario Analysis
12.3.1. FDA Approves Akebia Therapeutics' Vafseo for Treatment of Anemia in CKD Patients
12.3.2. FDA Approves Jardiance® for Chronic Kidney Disease, Specifies Non-Recommended Uses
12.3.3. Signify Health Launches In-Home Kidney Health Evaluations for Medicare Advantage Members
12.4. Strategy Analysis & Recommendation
List of Figures
FIGURE 1. CHRONIC KIDNEY DISEASE MARKET RESEARCH PROCESS
FIGURE 2. CHRONIC KIDNEY DISEASE MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
FIGURE 7. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 8. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 9. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 10. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
FIGURE 11. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 12. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 13. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 14. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 15. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 16. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 17. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 20. CHRONIC KIDNEY DISEASE MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 21. CHRONIC KIDNEY DISEASE MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. CHRONIC KIDNEY DISEASE MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 6. CHRONIC KIDNEY DISEASE MARKET DYNAMICS
TABLE 7. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 8. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY KIDNEY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
TABLE 12. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY URINE TESTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 14. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY KIDNEY TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 17. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 20. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FINERENONE, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 26. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
TABLE 27. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY POTASSIUM BINDERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 28. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
TABLE 29. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
TABLE 30. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 31. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 32. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 33. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CHRONIC INTERSTITIAL NEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 34. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIABETIC NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 35. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY GLOMERULONEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
TABLE 36. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HYPERTENSIVE NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 37. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY OBSTRUCTIVE NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
TABLE 38. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 39. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 40. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 41. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
TABLE 42. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
TABLE 43. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SPECIALITY TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
TABLE 44. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 45. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 46. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 47. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 48. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 49. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 50. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 51. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 52. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 53. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 54. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 55. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 56. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 57. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 58. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 59. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 60. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 61. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 62. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 63. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 64. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 65. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 66. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 67. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 68. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 69. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 70. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 71. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 72. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 73. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 74. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 75. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 76. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 77. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 78. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 79. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 80. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 81. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 82. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 83. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 84. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 85. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 86. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 87. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 88. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 89. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 90. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 91. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 92. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 93. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 94. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 95. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 96. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 97. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 98. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 99. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 100. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 101. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 102. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 103. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 104. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 105. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 106. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 107. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 108. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 109. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 110. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 111. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 112. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 113. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 114. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 115. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 116. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 117. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 118. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 119. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 120. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 121. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 122. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 123. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 124. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 125. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 126. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 127. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 128. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 129. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 130. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 131. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 132. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 133. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 134. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 135. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 136. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 137. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 138. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 139. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 140. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 141. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 142. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 143. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 144. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 145. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 146. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 147. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 148. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 149. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 150. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 151. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 152. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 153. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 154. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 155. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 156. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 157. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 158. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 159. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 160. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 161. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 162. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 163. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 164. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 165. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 166. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 167. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 168. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 169. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 170. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 171. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 172. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 173. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 174. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 175. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 176. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 177. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 178. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 179. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 180. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 181. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 182. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 183. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 184. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 185. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 186. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 187. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 188. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 189. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 190. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 191. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 192. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 193. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 194. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 195. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 196. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 197. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 198. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 199. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 200. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 201. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 202. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 203. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 204. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 205. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 206. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 207. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 208. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 209. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 210. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 211. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 212. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 213. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 214. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 215. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 216. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 217. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 218. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 219. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 220. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 221. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 222. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 223. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 224. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 225. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 226. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 227. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 228. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 229. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 230. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 231. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 232. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 233. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 234. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 235. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 236. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 237. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 238. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 239. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 240. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 241. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 242. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 243. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 244. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 245. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 246. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 247. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 248. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 249. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 250. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 251. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 252. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 253. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 254. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 255. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 256. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 257. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 258. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 259. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 260. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 261. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 262. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 263. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 264. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 265. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 266. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 267. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 268. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 269. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 270. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 271. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 272. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 273. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 274. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 275. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 276. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 277. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 278. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 279. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 280. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 281. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 282. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 283. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 284. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 285. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 286. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 287. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 288. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
TABLE 289. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
TABLE 290. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
TABLE 291. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
TABLE 292. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
TABLE 293. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
TABLE 294. CHRONIC KIDNEY DISEASE MARKET SHARE, BY KEY PLAYER, 2023
TABLE 295. CHRONIC KIDNEY DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

The leading players in the Chronic Kidney Disease Market, which are profiled in this report, include:
  • AbbVie Inc.
  • Allmed Medical Products Co., Ltd.
  • AngioDynamics, Inc.
  • Apotex Inc.
  • Asahi Kasei Corporation
  • AstraZeneca PLC
  • B. Braun SE
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • Centessa Pharmaceuticals Limited
  • DaVita Inc.
  • Dialife SA
  • Dr. Reddys Laboratories Ltd.
  • Evoqua Water Technologies LLC
  • Fresenius Medical Care AG
  • Galapagos NV
  • Hemoclean Co. Ltd.
  • JMS Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Medtronic PLC
  • Merck & Co., Inc.
  • Nikkiso Co., Ltd.
  • Nipro Corporation
  • Novartis AG
  • NxStage Medical Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals Inc.
  • Rockwell Medical Inc.
  • Sanofi S.A.
  • Teva Pharmaceutical Industries Ltd.
  • Toray Medical Co., Ltd.
  • Trivitron Healthcare
  • XORTX Therapeutics Inc.

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages189
PublishedOctober 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 136.56 Billion
Forecasted Market Value ( USD ) by 2030 $ 199.64 Billion
Compound Annual Growth Rate6.5%
Regions CoveredGlobal
No. of Companies Mentioned33

Related Topics

Related Reports

Clinical Nutrition For Chronic Kidney Diseases Market Size, Share & Trends Analysis Report by Product (Oral, Enteral Feeding Formulas, Parenteral Nutrition), Stage, Sales Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Clinical Nutrition For Chronic Kidney Diseases Market Size, Share & Trends Analysis Report by Product (Oral, Enteral Feeding Formulas, Parenteral Nutrition), Stage, Sales Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 125 Pages
  • Global
From
Anemia In Chronic Kidney Disease - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Anemia In Chronic Kidney Disease - Market Insight, Epidemiology and Market Forecast - 2034

  • Report
  • 200 Pages
  • Global
From
Chronic Kidney Disease Global Market Report 2024 - Product Image

Chronic Kidney Disease Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Kidney Disease Global Market Report 2024 - Product Image

Kidney Disease Global Market Report 2024

  • Report
  • 175 Pages
  • Global
From
Rare Kidney Diseases Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Disease Indications, Type of Molecule, Type of Biologics, Route of Administration, Type of Therapy, Key Geographical Regions, Leading Drug Developers and Sales Forecast - Product Image

Rare Kidney Diseases Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Target Disease Indications, Type of Molecule, Type of Biologics, Route of Administration, Type of Therapy, Key Geographical Regions, Leading Drug Developers and Sales Forecast

  • Report
  • 240 Pages
  • Global
From

About the Chronic Kidney Disease Market

The Chronic Kidney Disease (CKD) market is a subset of the Urology and Nephrology market. CKD is a long-term condition that affects the kidneys, and is characterized by a gradual loss of kidney function over time. It is a major cause of morbidity and mortality worldwide, and is associated with a range of other health conditions, including cardiovascular disease, diabetes, and hypertension. Treatment of CKD typically involves lifestyle modifications, medications, and dialysis. The Urology and Nephrology market is a rapidly growing sector, driven by the increasing prevalence of CKD and other kidney-related diseases. The market is expected to benefit from the development of new treatments and technologies, as well as the increasing demand for dialysis services. Some of the major companies in the CKD market include Baxter International, Fresenius Medical Care, DaVita, and NxStage Medical. These companies provide a range of products and services, including dialysis machines, dialysis consumables, and dialysis services. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.